9 research outputs found
Spécificité de la transformation sarcomateuse de la maladie de Recklinghaussen : a propos de deux cas et revue de la littérature
Abstract 5 à 10% des patients atteints de neurofibromatose de type 1 (NF1) développent des tumeurs malignes des gaines des nerfs périphériques (Malignant peripheral nerve sheath tumor: MPNST) contre 0.001% dans la population générale. A travers deux observations et une revue de la littérature nous discuterons la spécificité de la transformation sarcomateuse au cours de la neurofibromatose de type 1
Erratum to: Primary malignant non-Hodgkin’s lymphoma of the breast: a study of seven cases and literature review
Male breast cancer: a report of 127 cases at a Moroccan institution
Background: Male breast cancer (MBC) is a rare disease representing less than 1% of all malignancies in men and
only 1% of all incident breast cancers. Our study details clinico-pathological features, treatments and prognostic
factors in a large Moroccan cohort.
Findings: One hundred and twenty-seven patients were collected from 1985 to 2007 at the National Institute of
Oncology in Rabat, Morocco.
Median age was 62 years and median time for consultation 28 months. The main clinical complaint was a mass
beneath the areola in 93, 5% of the cases. Most patients have an advanced disease. Ninety-one percent of tumors
were ductal carcinomas.
Management consisted especially of radical mastectomy; followed by adjuvant radiotherapy and hormonal therapy
with or without chemotherapy. The median of follow-up was 30 months. The evolution has been characterized by
local recurrence; in twenty two cases (17% of all patients). Metastasis occurred in 41 cases (32% of all patients). The
site of metastasis was the bone in twenty cases; lung in twelve cases; liver in seven case; liver and skin in one case
and pleura and skin in one case.
Conclusion: Male breast cancer has many similarities to breast cancer in women, but there are distinct features
that should be appreciated. Future research for better understanding of this disease at national or international
level are needed to improve the management and prognosis of male patients
Entero-behçet et complications : A propos d’un cas et revue de litterature.
Nous présentons dans ce travail une mise au point sur les localisations intestinales de la maladie de Behçet (entéro-BEHÇET) à travers une observation colligée à l’Hôpital Avicenne dans le service de Chirurgie « I » (Urgences Chirurgicales Viscérales) en 2008.
L’entéro-BEHÇET, rare en Europe, est beaucoup plus fréquente en Asie. Il a été décrit pour la première fois en 1940. On relève une prédominance féminine en occident et masculine au Japon et dans les pays du pourtour méditerranéen.
L’âge moyen de survenue des atteintes intestinales se situe entre la 3ème et la 4ème décade soit 4 à 9 ans après le début des premiers symptômes (moyenne : 6ans) de la maladie de BEHÇET.
Ces lésions intestinales peuvent se révéler par un tableau de colite ou d’entéro-colite (aigüe) avec ou sans signes de rectite ou par une complication aigüe (perforation, hémorragie, abcès, fistules).
Les aspects radiologiques, endoscopiques, histologiques ne sont pas spécifiques. Cependant, l’entéro-BEHÇET doit être reconnu et différencié des autres maladies inflammatoires de l’intestin associées à des manifestations systémiques (maladie de CROHN, RECTO-COLITE-HEMORRAGIQUE) en raison du risque élevé de perforations des ulcérations (dans 26% à 75% des cas selon les séries) souvent multiples, et de récidive postopératoires (jusqu’à 44% des cas) imposant une approche chirurgicale spécifique
Primary malignant non-Hodgkin’s lymphoma of the breast: a study of seven cases and literature review
Abstract Introduction Primary breast lymphoma is an uncommon disease with poor clinical outcome. Breast lymphomas present less than 0.5% of malignant breast neoplasms and 2.2% of extranodal lymphomas. This study investigated the clinicopathological features and optimal treatment of PBL. Case presentations Clinical records of seven Moroccan PBL patients, treated at the National Institute of Oncology, Rabat, Morocco, from 2002 to 2010, were reviewed. Six of the patients were women and one a man, with ages ranging from 32 to 76. Five patients had stage IE and two stage IIE. All of the patients were classified with DLBCL. Of seven patients, one received a mastectomy and three excision of the breast lesion. Axillary dissection was performed in three patients. Two patients received chemotherapy followed by radiotherapy, while four received chemotherapy alone. Complete remission (CR) following primary treatment for all patients with PBL except in two cases was obtained. In one patient, recurrence occurred. Conclusions There is no consensus on the question of how to best treat PBL: Mastectomy offers no benefit in the treatment of PBL. The combined therapy approach, with chemotherapy and radiotherapy, is the most successful treatment. PBL is poorly represented in rituximab-containing trials in DLBCL patients; there is not much experience with this agent in breast DLBCL. Because of the high incidence of central nervous system (CNS) involvement in PBL patients, many authors strongly believe that patients with aggressive forms of PBL should receive CNS infiltration prophylaxis.</p
Correction: Primary malignant non-Hodgkin’s lymphoma of the breast: a study of seven cases and literature review
Primary malignant non-Hodgkin’s lymphoma of the breast: a study of seven cases and literature review
AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan)
Purpose: Cancer is a leading cause of mortality worldwide. Its incidence is still increasing, particularly in developing countries. Recent progresses further strengthen the differences between low/middle and high-income countries. This situation calls for joint action to reduce inequities in cancer outcomes among the patients. The Association of Radiotherapy and Oncology of the Mediterranean Area (AROME) and the European School of Oncology (ESO), have initiated joint conferences devoted to access to innovations in oncology in the Mediterranean area. The heterogeneity of the economic, political and cultural situations of the different participating countries, offers the opportunity to develop consensus conference